Connected profiles6
Exact peptide identities attached to retained registry observations carrying this condition label.
Coverage-gated living condition brief
Overweight peptide evidence brief
A cited Overweight peptide evidence brief across 11 exact-label ClinicalTrials.gov records, 6 connected profiles, and 4 registry-update years. The label is copied from each retained registry version and does not imply that PeptideScanner has verified a diagnosis, treatment relationship, or study result.
Registry records
11 selected records.
Connected peptides
6 profiles.
Registry update years
2020–2026 in selected records.
Direct collection answer · published August 17, 2026
What peptide evidence does PeptideScanner carry for Overweight?
PeptideScanner’s selected collection contains 11 retained ClinicalTrials.gov records carrying the exact condition label “Overweight,” connected to 6 peptide profiles across 4 registry-update years.
That answer describes this collection and the exact cited registry observations below. It is not a conclusion about whether any peptide treats Overweight, and it is not a safety or efficacy assessment.
Indication intelligence
Selected evidence landscape
Trial phases4
Phase labels copied from the retained ClinicalTrials.gov versions.
Phase 3 (8)Phase 2 (1)Not applicable (1)Phase 1 (1)
Registry statuses4
Overall statuses at each retained observation, not necessarily current today.
Recruiting (4)Completed (4)Active, not recruiting (2)Not yet recruiting (1)
Across the connected peptide profiles, PeptideScanner also carries 189 selected PubMed records and 7 selected Drugs@FDA applications. Those records are profile context only; PeptideScanner does not claim they concern Overweight unless their own cited source says so.
Related profile context
Literature connected through these peptide profiles
This is a bounded sample of up to six PubMed bibliography records connected through peptide profiles on this hub, not the total profile literature count above. They are not condition-matched records, and their presence does not establish that they concern Overweight.
Semaglutide · source record 2026-08-15
Validation of a Pharmacist-Led Semaglutide Prescribing Algorithm for Type 2 Diabetes and Chronic Kidney Disease: Research Letter.
PubMed lists PMID 42602345 in Canadian journal of kidney health and disease as Journal Article, with publication-date metadata of 2026-08-13 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
Open attributed literature record →Maridebart cafraglutide · source record 2026-08-13
Design and therapeutic rationale of antibody-peptide conjugates: insights from maridebart cafraglutide (AMG133) and emerging applications.
PubMed lists PMID 42592044 in Antibody therapeutics as Journal Article, Review, with publication-date metadata of 2026-06-01 (day precision). PeptideScanner associated the retained record with the identity slug maridebart-cafraglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
Open attributed literature record →Retatrutide · source record 2025-09-02
Retatrutide.
PubMed lists PMID 39429457 in Clinical diabetes : a publication of the American Diabetes Association as Journal Article, with publication-date metadata of 2024-08-01 (day precision). PeptideScanner associated the retained record with the identity slug retatrutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
Open attributed literature record →Tirzepatide · source record 2026-08-14
Inflammation-mediated facial nodules to compounded tirzepatide.
PubMed lists PMID 42598502 in JAAD case reports as Letter, with publication-date metadata of 2026-06-17 (day precision). PeptideScanner associated the retained record with the identity slug tirzepatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
Open attributed literature record →Semaglutide · source record 2026-08-13
Semaglutide and Non-arteritic Anterior Ischemic Optic Neuropathy: A Systematic Review and Narrative Synthesis.
PubMed lists PMID 41938304 in AACE endocrinology and diabetes as Journal Article, Review, with publication-date metadata of 2026-01-17 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
Open attributed literature record →Retatrutide · source record 2025-07-03
Triple-Hormone-Receptor Agonist Retatrutide for Obesity.
PubMed lists PMID 37888925 in The New England journal of medicine as Letter, Comment, with publication-date metadata of 2023-10-26 (day precision). PeptideScanner associated the retained record with the identity slug retatrutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
Open attributed literature record →Collection change ledger
Recently changed records on this condition hub
These events come only from the exact registry records shown on this page. The condition label does not establish a diagnosis, treatment relationship, or scientific agreement.
Record added
ClinicalTrials.gov record NCT05929079
PeptideScanner retained ClinicalTrials.gov record NCT05929079 at 2026-08-10T18:10:04.224Z. Its registry update date was 2026-07-30, and PeptideScanner's reviewed identity mapping was retatrutide.
- PeptideScanner change date
- August 14, 2026
- Cited source date
- July 30, 2026
- Evidence lane
- Clinical trials
Record added
ClinicalTrials.gov record NCT06965413
PeptideScanner retained ClinicalTrials.gov record NCT06965413 at 2026-08-13T05:52:27.007Z. Its registry update date was 2026-08-11, and PeptideScanner's reviewed identity mapping was tirzepatide.
- PeptideScanner change date
- August 14, 2026
- Cited source date
- August 11, 2026
- Evidence lane
- Clinical trials
Record added
ClinicalTrials.gov record NCT07220759
PeptideScanner retained ClinicalTrials.gov record NCT07220759 at 2026-08-13T05:52:27.019Z. Its registry update date was 2026-08-03, and PeptideScanner's reviewed identity mapping was cagrilintide.
- PeptideScanner change date
- August 14, 2026
- Cited source date
- August 3, 2026
- Evidence lane
- Clinical trials
Exact-record source chronology
Overweight registry timeline
Years come from the last-update date on each retained ClinicalTrials.gov observation. They show source chronology, not when PeptideScanner added the record and not a continuous monitoring guarantee.
2026
8 recordsTirzepatide · 2026-08-11
ClinicalTrials.gov record NCT06965413
Active, not recruiting at the retained observation.
Open cited registry record →Maridebart cafraglutide · 2026-08-04
ClinicalTrials.gov record NCT07684235
Recruiting at the retained observation.
Open cited registry record →Cagrilintide · 2026-08-04
ClinicalTrials.gov record NCT07745504
Not yet recruiting at the retained observation.
Open cited registry record →Cagrilintide · 2026-08-03
ClinicalTrials.gov record NCT07220759
Active, not recruiting at the retained observation.
Open cited registry record →Retatrutide · 2026-07-30
ClinicalTrials.gov record NCT05929079
Completed at the retained observation.
Open cited registry record →Semaglutide · 2026-07-28
ClinicalTrials.gov record NCT07732426
Recruiting at the retained observation.
Open cited registry record →Maridebart cafraglutide · 2026-07-24
ClinicalTrials.gov record NCT07037433
Recruiting at the retained observation.
Open cited registry record →Mazdutide · 2026-05-27
ClinicalTrials.gov record NCT07469800
Recruiting at the retained observation.
Open cited registry record →2024
1 recordSemaglutide · 2024-08-30
ClinicalTrials.gov record NCT03574597
Completed at the retained observation.
Open cited registry record →2021
1 recordSemaglutide · 2021-11-11
ClinicalTrials.gov record NCT03611582
Completed at the retained observation.
Open cited registry record →2020
1 recordSemaglutide · 2020-12-24
ClinicalTrials.gov record NCT03842202
Completed at the retained observation.
Open cited registry record →- Condition matching is limited to exact labels on retained ClinicalTrials.gov v3 observations; PeptideScanner does not merge related diagnoses or synonyms.
- Coverage is selective and historical, not a complete or continuously current account of the registry or PubMed.
- The brief does not synthesize study outcomes, compare interventions, or make safety, efficacy, diagnosis, or treatment claims.